Invenomic Capital Exits $24M Haemonetics Stake Amid Med-Tech Underperformance
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology. The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.
Key Takeaways
- Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology.
- The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.
Mentioned
Key Intelligence
Key Facts
- 1Invenomic Capital Management sold its entire stake of 498,317 shares in Haemonetics Corporation.
- 2The total value of the exit was approximately $24.29 million as of the February 17, 2026 filing.
- 3Haemonetics (HAE) shares were priced at $58.58, representing a 9% decline over the past year.
- 4The exit reduced HAE from 1.2% of Invenomic's 13F AUM to zero.
- 5Haemonetics underperformed the S&P 500 by roughly 25% during the same 12-month period.
| Metric | |||
|---|---|---|---|
| Position Status | Exited (0%) | Top Holding (3.4%) | Top Holding (2.8%) |
| Invenomic Value | $0.00M | $69.64M | $58.66M |
| Sector Focus | Blood/Plasma Tech | Pharmaceuticals | Dental/Med-Devices |
Who's Affected
Analysis
The recent SEC filing from Invenomic Capital Management revealing a total exit from Haemonetics Corporation (HAE) marks a significant shift in the medical device investment landscape. Selling nearly half a million shares valued at over $24 million, the fund has completely removed HAE from its portfolio, where it previously held a 1.2% weight. This move is particularly striking given Haemonetics' entrenched position in the plasma collection and blood management markets—sectors traditionally viewed as resilient. However, with the stock down 9% over the last twelve months while the S&P 500 climbed 16%, the opportunity cost of holding HAE likely became too high for active managers seeking alpha in a recovering healthcare market.
Haemonetics operates at the critical intersection of medical hardware and health IT, providing the automated systems and proprietary software that power plasma centers and hospital blood banks. While the company has historically benefited from the recovery in plasma collection volumes post-pandemic, it faces headwinds including rising operational costs for healthcare providers and a shifting regulatory environment for blood products. The decision by Invenomic to reallocate capital into entities like Viatris (VTRS) and Dentsply Sirona (XRAY) suggests a preference for value-oriented healthcare plays or sectors with more immediate catalysts for growth, such as pharmaceutical consolidation or dental technology recovery.
Selling nearly half a million shares valued at over $24 million, the fund has completely removed HAE from its portfolio, where it previously held a 1.2% weight.
The broader medical device sector has seen a divergence in performance. Companies focused on high-growth areas like diabetes tech or cardiovascular interventions have thrived, while 'bread and butter' hospital supply and blood management firms have struggled with margin compression. For Haemonetics, the challenge lies in maintaining its dominance in plasma collection while expanding its software-as-a-service (SaaS) offerings for blood management. Investors are increasingly looking for med-tech stories that offer high-margin recurring revenue, and while Haemonetics has a software component, its heavy reliance on disposables and hardware sales makes it sensitive to supply chain fluctuations and hospital capital expenditure (CAPEX) cycles.
What to Watch
Furthermore, the exit of a major institutional holder often triggers a 'wait and see' approach among other mid-sized funds. If Haemonetics cannot demonstrate a clear path to outperforming the broader healthcare indices, it may face further institutional selling pressure. Analysts will be closely watching the company’s upcoming quarterly reports for signs of margin expansion in its Hospital business and volume growth in Plasma. The pivot by Invenomic into Global Payments and Akamai also hints at a broader macro-strategy that favors technology and payment infrastructure over specialized medical hardware in the current interest rate environment.
Looking ahead, the medical device industry remains in a state of consolidation and refinement. For Haemonetics, the path to regaining investor confidence likely involves aggressive innovation in its hemostasis analyzer line and deeper integration of its software platforms to provide end-to-end visibility for blood centers. For now, the $24 million exit serves as a cautionary signal that even established leaders in critical healthcare niches are not immune to portfolio rebalancing when performance lags the wider market. Investors should monitor whether other institutional holders follow Invenomic's lead or if this exit creates a value-entry point for those betting on a plasma market resurgence.
Sources
Sources
Based on 2 source articles- Jonathan Ponciano (us)What Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9% This Past YearMar 20, 2026
- fool.comWhat Investors Should Know About a $24 Million Exit From a Medical Device Stock Down 9 % This Past YearMar 20, 2026
Cite This Page
"Invenomic Capital Exits $24M Haemonetics Stake Amid Med-Tech Underperformance." Healthcare Intelligence Brief, March 21, 2026. https://gethealthbrief.com/story/invenomic-capital-exits-haemonetics-stake
How we covered this story
Every story in our healthcare coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the healthcare space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
Sources are only linked to a story once they clear our classification pipeline at a minimum 35 percent relevance threshold. According to that methodology, reviewed July 2026, this follows multi-source corroboration standards recommended by journalism research bodies such as the Reuters Institute for the Study of Journalism.
See something wrong in this story — a wrong fact, a broken source link, a misattributed entity? Report a data issue.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled healthcare-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |